Disruption of fungal cell wall by antifungal Echinacea extracts

Medical Mycology

Volumn 48, Issue 7, 2010, Pages 949-958

  Mir Rashed, Nadereh ^a   Cruz, Isabel ^a   Jessulat, Matthew ^a   Dumontier, Michel ^a   Chesnais, Claire ^a   Ng, Juliana ^a   Amiguet, Virginie Treyvaud ^b   Golshani, Ashkan ^a   Arnason, John T ^b   Smith, Myron L ^a  

^a CARLETON UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Antifungal mode of action; Chemical genetic profile; Echinacea; Gene deletion array; Natural health product; Yeast cell wall mutants

Indexed keywords

ECHINACEA PURPUREA EXTRACT;

ANTIFUNGAL ACTIVITY; ARTICLE; CELL DEATH; CELL DISRUPTION; CELL WALL; CHEMICAL GENETICS; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; FLUORESCENCE MICROSCOPY; FOLLOW UP; FUNGAL CELL; FUNGUS MUTANT; GENE DELETION; MUTATION; NONHUMAN; SACCHAROMYCES CEREVISIAE; ULTRASOUND;

ANTIFUNGAL AGENTS; CELL WALL; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, FUNGAL; ECHINACEA; GENE DELETION; GENES, FUNGAL; MICROBIAL SENSITIVITY TESTS; PLANT EXTRACTS; POINT MUTATION; SACCHAROMYCES CEREVISIAE; ULTRAVIOLET RAYS;

BACTERIA (MICROORGANISMS); FILOBASIDIELLA NEOFORMANS; SACCHAROMYCES CEREVISIAE;

EID: 77957734375     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693781003767584     Document Type: Article

References (51)

1. Shemluck M. Medicinal and other uses of the Compositae by Indians in the United States and Canada J Ethnopharmacol 1982; 5: 303-358.
2. Small E, Catling PM. Canadian Medicinal Crops. Ottawa, ON: NRC Research Press, 1999:47-52.
3. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. In: Advance Data from Vital and Health Statistics; number 343. Hyattsville, Maryland: National Center for Health Statistics, 2004.
4. Brevoort P. The booming US botanical market. HerbalGram 1998; 44: 33-48.
5. Binns S, Baum BR, Arnason JT. Taxonomic revision of the genus Echinacea (Heliantheae: Asteraceae). Syst Bot 2002; 27: 610-632.
6. Binns SE, Hudson J, Merali S, Arnason JT. Antiviral activity of characterized extracts from Echinacea spp. (Heliantheae: Asteraceae) against Herpes simplex virus (HSV-I). Planta Med 2002; 68: 780-783.
7. Shah SA, Sander S, White CM, Rinaldi M, Coleman CI. Evaluation of Echinacea for the prevention and treatment of the common cold: a meta-analysis. Lancet Infect Dis 2007; 7: 473-480.
8. Goel V, Chang C, Slama J, et al. Echinacea stimulates macrophage function in the lung and spleen of normal rats. J Nutr Biochem 2002; 13: 487.
9. Hobbs C. Echinacea: A literature review; botany, history, chemistry, pharmacology, toxicology, and clinical uses. HerbalGram 1994; 30:
10. Hudson J, Vimalanathan S, Kang L, et al. Characterization of anti-viral activities in Echinacea root preparations. Pharm Biol 2005; 43: 790-796.
11. Merali S, Binns S, Paulin-Levasseur M, et al. Antifungal and anti-inf ammatory activity of the genus Echinacea. Pharm Biol 2003; 41: 412-420.
12. Wacker A, Hilbig W. Virus-Inhibition by Echinacea purpurea. Planta Med 1978; 33: 89-102.
13. Awang DVC, Kindack DG. Herbal medicine, Echinacea. Can Phar-maceut J 1991; 124: 512-515.
14. Bauer R. Echinacea-Biological effects and active principles. In: Lawson LD, Bauer R, (eds.), Phytomedicines of Europe-Chemistry and Biological Activity. Washington, DC: ACS Books, 1998: 140-157.
15. Bradley PR. In: British Herbal Compendium Vol 1. Bournemouth, UK: British Herbal Medicine Association, 1992: 81.
16. Letchamo W, Livesey J, Arnason JT, Bergeron C, Krutilina VS. Cichoric acid and isobutylamide content in Echinacea purpurea as inf uenced by f ower developmental stages. In: J. Janick, (ed.) Perspectives on New Crops and New Uses. Alexandria, VA: ASHS Press, 1999.
17. Percival SS. Use of Echinacea in medicine. Biochem Pharmacol 2000; 60: 155-158.
18. Matthias A, Addison RS, Penman KG, et al. Echinacea alkamide disposition and pharmacokinetics in humans after tablet ingestion. Life Sci 2005; 77: 2018-2029.
19. Matthias A, Blanchf eld JT, Penman KG, et al. Permeability studies of alkylamides and caffeic acid conjugates from Echinacea using a Caco-2 cell monolayer model. J Clin Pharm Ther 2004; 29: 7-13.
20. Woelkart K, Koidl C, Grisold A, et al. Bioavailability and pharma-cokinetics of alkamides from the roots of Echinacea angustifolia in humans. J Clin Pharmacol 2005; 45: 683-689.
21. Binns SE, Livesey JF, Arnason JT, Baum BR. Phytochemical varia-tion in Echinacea from roots and f owerheads of wild and cultivated populations. J Agric Food Chem 2002; 50: 3673-3687.
22. Sharma M, Arnason JT, Burt A, Hudson JB. Echinacea extracts modu-late the pattern of chemokine and cytokine secretion in rhinovirus-infected and uninfected epithelial cells. Phytother Res 2006; 20: 147-152.
23. Binns SE, Purgina B, Bergeron C, et al. Light-mediated activity of Echinacea extracts. Planta Medica 2000; 44: 1494-1498.
24. Parsons AB, Brost RL, Ding H, et al. Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. Nat Biotechnol 2004; 22: 62-69.
25. Vimalanathan S, Kang L, Amiguet VT, et al. Echinacea purpurea aerial parts contain multiple antiviral compounds. Pharm Biol 2005; 43:740-745.
26. Tong AH, Evangelista M, Parsons AB, et al. Systematic genetic analy-sis with ordered arrays of yeast deletion mutants. Science 2001; 294: 2364-2368.
27. Memarian N, Jessulat M, Alirezaie J, et al. Colony size measurement of the yeast gene deletion strains for functional genomics. BMC Bioinf2007; 8:117.
28. Ruiz C, Cid VJ, Lussier M, Molina M, Nombela C. A large-scale sonication assay for cell wall mutant analysis in yeast. Yeast 1999; 15: 1001-1008.
29. Liu Y, Murphy PA. Alkamide stability in Echinacea purpurea extracts with and without phenolic acids in dry f lms and in solution. J Agric Food Chem 2007; 55:120-126.
30. Dumontier M, Green JR, Golshani A, et al. Yeast features: Identify-ing signif cant features shared among yeast proteins for functional genomics. Nature Precedings 2008:(npre. 2008. 2311. 2001).
31. Towers GHN, Page JE, Hudson JB. Light-mediated biological activi-ties of natural products from plants and fungi. Curr Org Chem 1997; 1: 395-414.
32. Bowen S, Wheals AE. Incorporation of Sed1p into the cell wall of Saccharomyces cerevisiae involves KRE6. FEMS Yeast Res 2004; 4: 731-735.
33. Tomishige N, Noda Y, Adachi H, et al. Mutations that are syntheti-cally lethal with a gas1Delta allele cause defects in the cell wall of Saccharomyces cerevisiae. Mol Genet Genomics 2003; 269: 562-573.
34. Vai M, Gatti E, Lacana E, Popolo L, Alberghina L. Isolation and deduced amino-acid-sequence of the gene encoding Gp115, a yeast glycophospholipid- anchored protein containing a serine-rich region. J Biol Chem 1991; 266: 12242-12248.
35. Popolo L, Vai M, Gatti E, et al. Physiological analysis of mutants in-dicates involvement of the Saccharomyces cerevisiae GPI-anchored protein gp115 in morphogenesis and cell separation. J Bacteriol 1993; 175: 1879-1885.
36. Dallies N, Francois J, Paquet V A new method for quantitative deter-mination of polysaccharides in the yeast cell wall. Application to the cell wall defective mutants of Saccharomyces cerevisiae. Yeast 1998; 14: 1297-1306.
37. Ram AF, Kapteyn JC, Montijn RC, et al. Loss of the plasma membrane-bound protein Gas1p in Saccharomyces cerevisiae results in the release of beta1, 3-glucan into the medium and induces a com-pensation mechanism to ensure cell wall integrity. J Bacteriol 1998; 180: 1418-1424.
38. Markovich S, Yekutiel A, Shalit I, Shadkchan Y, Osherov N. Genomic approach to identif cation of mutations affecting caspofungin suscep-tibility in Saccharomyces cerevisiae. Antimicrob Agents Chemother 2004; 48:3871-3876.
39. Jungmann J, Rayner JC, Munro S. The Saccharomyces cerevisiae protein Mnn10p/Bed1p is a subunit of a Golgi mannosyltransferase complex. J Biol Chem 1999; 274: 6579-6585.
40. Neiman AM, Mhaiskar V, Manus V, Galibert F, Dean N. Saccharomy-ces cerevisiae HOC1, a suppressor of pkc1, encodes a putative glyco-syltransferase. Genetics 1997; 145: 637-645.
41. Wang TT, Bretscher A. The Rho-Gap encoded by Bem2 regu-lates cytoskeletal structure in budding yeast. Mol Biol Cell 1995; 6: 1011-1024.
42. Cabib E, Drgonova J, Drgon T. Role of small G proteins in yeast cell polarization and wall biosynthesis. Annu Rev Biochem 1998; 67: 307-333.
43. Yamochi W, Tanaka K, Nonaka H, et al. Growth site localization of Rho1 small Gtp-binding protein and its involvement in bud formation in Saccharomyces cerevisiae. J Cell Biol 1994; 125: 1077-1093.
44. Kawakami T, Chiba T, Suzuki T, et al. NEDD8 recruits E2-ubiquitin to SCF E3 ligase. EMBO J 2001; 20: 4003-4012.
45. Liakopoulos D, Doenges G, Matuschewski K, Jentsch S. A novel pro-tein modif cation pathway related to the ubiquitin system. EMBO J 1998; 17:2208-2214.
46. de Groot PWJ, Ruiz C, Vázquez de Aldana CR, et al. A genomic approach for the identif cation and classif cation of genes in-volved in cell wall formation and its regulation in Saccharomyces cerevisiae. Comp Funct Genomics 2001; 2: 124-142.
47. Chiou CC, Groll AH, Walsh TJ. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 2000; 5: 120-135.
48. Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall devel-opment. Annu Rev Microbiol 1994; 48: 471-497.
49. Hector RF. Compounds active against cell walls of medically impor-tant fungi. Clin Microbiol Rev 1993; 6: 1-21.
50. Hodges PE, McKee AH, Davis BP, Payne WE, Garrels JI. The Yeast Proteome Database (YPD): a model for the organization and presen-tation of genome-wide functional data. Nucleic Acids Res 1999; 27: 69-73
51. SGD project [Saccharomyces Genome Database]. Accessed August 2006 from: http://www. yeastgenome. org/